In this report, the Cancer Biologics Market has been segmented by Type, Drug Class, Application, End-use, and Geography.

Cancer Biologics Market, Segmentation by Type

The Cancer Biologics Market has been segmented by Type into Monoclonal antibodies, Vaccines, Cell and gene therapy and Others.

Monoclonal Antibodies
Monoclonal antibodies represent the largest segment of the cancer biologics market, contributing approximately 45–50% of the total market share. These highly targeted therapies are designed to identify and attack specific cancer cells while sparing healthy tissues. Their effectiveness in treating a wide range of cancers, including breast, lung, and colorectal cancers, has significantly propelled their adoption. Moreover, ongoing advancements in antibody design and engineering continue to support their expanding application in oncology.

Vaccines
Cancer vaccines make up around 15–20% of the market, and this share is expected to grow as the focus on immunotherapy intensifies. These vaccines come in two primary forms—therapeutic vaccines that stimulate the body’s immune response to attack cancer cells, and prophylactic vaccines like the HPV vaccine that help prevent virus-related cancers. With increasing global awareness and innovation in cancer immunization strategies, vaccines are gradually becoming a pivotal part of biologic cancer therapies.

Cell and Gene Therapy
Accounting for nearly 20–25% of the market, cell and gene therapies are quickly emerging as transformative options in the fight against cancer. Techniques like CAR-T cell therapy, which genetically reprograms patient cells to target malignancies, are showing exceptional results, especially in blood cancers. As regulatory agencies approve more of these innovative treatments and investment pours into gene-based oncology research, this segment is anticipated to expand significantly in the near future.

Others
The “Others” category includes additional biologics such as cytokines and fusion proteins and comprises around 5–10% of the market. While currently smaller in scope, these therapies play critical roles in specific treatment regimens and are often used in combination with more mainstream approaches. Continued research and development may enhance their future relevance and expand their role in personalized cancer treatment strategies.

Cancer Biologics Market, Segmentation by Drug Class

The Cancer Biologics Market has been segmented by Drug Class into Monoclonal Antibodies, Cancer Growth Inhibitors, Vaccines, Recombinants Proteins, CAR-T Cells, Angiogenesis Inhibitors, Interleukins, Interferons, Gene Therapy, and Others.

Cancer Growth Inhibitors and Angiogenesis Inhibitors
Cancer growth inhibitors represent a major segment of the cancer biologics market, holding approximately 25–30% of the total market share. These agents disrupt the molecular signals that drive cancer cell proliferation, thereby slowing or stopping tumor development. Alongside them, angiogenesis inhibitors—accounting for around 10–12%—work by cutting off the blood supply that tumors need to grow. These drug classes are widely used in the treatment of solid tumors and have proven effective in halting disease progression.

Vaccines and Recombinant Proteins
Cancer vaccines and recombinant proteins collectively make up about 20–25% of the market. Vaccines, both therapeutic and prophylactic, are gaining popularity due to advancements in immunotherapy and patient-specific treatments. Recombinant proteins, which are bioengineered to support immune function or replace deficient proteins, play a crucial role in managing cancer symptoms and boosting treatment response. This growing segment highlights the increasing reliance on biologically engineered agents in cancer care.

Interleukins, Interferons, and Others
Interleukins and interferons contribute around 10–15% to the cancer biologics market. These immune-stimulating agents are used to enhance the body’s ability to detect and destroy cancerous cells. The remaining 5–8% is comprised of the “Others” category, which includes a variety of emerging or adjunct biologic therapies. While smaller in size, these treatments are often vital in specialized or combination therapy settings, and may see expanded roles as clinical research progresses.

CAR-T Cells and Gene Therapy
CAR-T cell therapies and gene therapy drugs together account for nearly 15–20% of the market. CAR-T technology involves modifying a patient’s own T-cells to identify and attack cancer cells, offering hope for patients with resistant forms of cancer. Gene therapy, although still in developmental stages, is rapidly advancing and holds promise for correcting genetic defects at the source. These innovative treatments represent the forefront of oncology research and are expected to drive future market growth.

Cancer Biologics Market, Segmentation by Application

The Cancer Biologics Market has been segmented by Application into Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Gastric Cancer, Ovarian Cancer, Skin Cancer, Liver Cancer, and Others.

Blood Cancer and Lung Cancer
Blood cancer leads the cancer biologics market by application, making up approximately 25–30% of the total share. This is largely due to the strong effectiveness of biologic therapies—such as monoclonal antibodies and CAR-T cells—in treating blood-related malignancies including leukemia, lymphoma, and multiple myeloma. Lung cancer follows as a close second, with a share of about 20–22%. The increasing incidence of non-small cell lung cancer (NSCLC) and the growing adoption of targeted therapies have significantly boosted demand in this segment.

Breast and Colorectal Cancer
Breast cancer applications represent around 15–18% of the market, supported by biologic drugs like HER2 inhibitors that are widely used in targeted treatment plans. The expansion of personalized oncology and public health initiatives focused on early detection are further driving this segment. Colorectal cancer, accounting for nearly 10–12%, benefits from continuous advancements in immuno-oncology and targeted drug delivery systems, enhancing both treatment effectiveness and patient survival rates.

Prostate and Gastric Cancer
Prostate cancer comprises roughly 8–10% of the market, fueled by rising cases among aging male populations and the use of biologics in hormone-responsive therapies. Gastric cancer, while somewhat limited in prevalence, still captures 5–7% of the market. Recent progress in biologic targeting of HER2-positive gastric cancers has opened new treatment pathways, increasing the relevance of biologics in gastrointestinal oncology.

Ovarian, Skin, Liver Cancer, and Others
Ovarian, skin, and liver cancers together represent about 8–10% of the cancer biologics market. Biologics such as immune checkpoint inhibitors and targeted immunotherapies are making significant strides in these cancers. The “Others” category, accounting for 3–5%, includes rare and less common cancers that nonetheless offer growth opportunities for biologic treatment development as innovation in precision oncology continues to evolve.

Cancer Biologics Market, Segmentation by End-Use

In this report, the Cancer Biologics Market has been segmented by End-Use into Hospitals, Cancer Center, and Academics & Research Institutes.

Hospitals
Hospitals lead the cancer biologics market in terms of end-use, contributing approximately 60–65% of the total market share. Their dominance stems from their advanced healthcare infrastructure, which includes diagnostic labs, infusion facilities, and trained oncologists capable of administering complex biologic treatments. As primary treatment centers, hospitals frequently initiate and manage long-term cancer care, making them a crucial channel for the adoption and distribution of biologic therapies.

Cancer Centers
Cancer centers hold a substantial 25–30% share in the cancer biologics market. These dedicated oncology facilities are known for their focus on personalized medicine and innovative cancer treatment protocols. Equipped with state-of-the-art technology and multidisciplinary expertise, cancer centers often participate in clinical trials and specialized biologic interventions, especially in regions with high healthcare expenditure and robust research funding.

Academics & Research Institutes
Academic and research institutes account for around 5–10% of the market. Though not always directly involved in routine patient care, their impact on the biologics ecosystem is significant. These institutions are pivotal in conducting preclinical and clinical research, discovering new biologic targets, and testing experimental therapies. Their work forms the foundation for future treatment innovations and supports the continuous evolution of cancer biologics.

Cancer Biologics Market, Segmentation by Geography

In this report, the Cancer Biologics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Cancer Biologics Market Share (%), by Geographical Region, 2024

North America
North America dominates the cancer biologics market, holding an estimated 40–45% share. This strong market position is fueled by advanced healthcare infrastructure, significant R&D investments, and the presence of leading biotechnology and pharmaceutical firms. The United States is particularly influential, with its rapid adoption of innovative cancer biologic therapies and robust support for oncology research and clinical development.

Europe
Europe ranks second in terms of market share, contributing about 25–28%. The region's performance is supported by universal healthcare access, high cancer prevalence, and strong governmental backing for research initiatives. Countries such as Germany, France, and the U.K. are leading users of biologic therapies in oncology, benefiting from established healthcare networks and progressive reimbursement policies that facilitate patient access.

Asia Pacific
Asia Pacific represents approximately 18–20% of the global market and is experiencing the fastest growth rate. Key drivers include increasing cancer incidence, rising healthcare investments, and improved medical infrastructure across developing nations. Countries like China, India, and Japan are emerging as significant markets due to heightened awareness, supportive regulations, and expanding biotechnology capabilities in cancer care.

Middle East & Africa and Latin America
The Middle East & Africa and Latin America collectively account for about 8–10% of the cancer biologics market. These regions are seeing gradual improvement through enhanced cancer screening programs and growing investments in healthcare infrastructure. Despite these efforts, limited access to biologics and uneven healthcare quality continue to pose challenges to broader market penetration.

This report provides an in depth analysis of various factors that impact the dynamics of Cancer Biologics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Key players in Cancer Biologics Market include:

• Takeda Pharmaceutical Company Limited
• Duality Biologics
• Amgen, Inc.
• Glenmark Pharmaceuticals Ltd
• BioNTech
• Pfizer Inc.
• AstraZeneca PLC
• Biocon Biologics
• Bristol Myers Squibb Company
• Celgene Corporation
• Amgen Inc.
• Dr. Reddy’s Laboratories
• Abbott
• AbbVie Inc.
• Johnson & Johnson
• Biogen Inc.
• GSK PLC
• Merck & Co. Inc.
• Gilead Sciences Inc.
• Sanofi S.A.
• Hoffmann-La Roche Ltd.
• Novartis International AG
• Eli Lilly and Company
• TFC Therapeutics

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis